Document:

EX-10.1

 Exhibit 10.1 

Execution Copy 

Amendment to the Employee Matters Agreement 

This Amendment to the Employee Matters Agreement (this “Amendment”) by and among Nutrition & Biosciences, Inc.
(“Spinco”), DuPont de Nemours, Inc. (“Remainco”) and International Flavors & Fragrances Inc. (“RMT Partner” and, together with Spinco and Remainco, the “Parties”) dated as of January 22, 2021.

 WHEREAS, the Parties entered into an Employee Matters Agreement dated as of December 15, 2019 (as it may be amended, the
“EMA”); 
 WHEREAS, the Parties wish to amend certain provisions of the EMA and clarify the interpretation of certain provisions
of the EMA, in each case as set forth in this Amendment; 
 NOW, THEREFORE, the Parties hereby agree as set forth below. 

A.    GENERAL MATTERS 

1.    Capitalized terms used but not defined in this Amendment shall have the meaning ascribed to them in the EMA. 

2.    To the extent any of the provisions agreed to herein are in direct conflict with the EMA, the Parties agree the EMA
shall be deemed amended thereby effective as of immediately prior to the Spinco Distribution. 
 3.    To the extent any
of the provisions agreed to herein are not in direct conflict with the EMA, the Parties agree that the EMA is amended effective as of immediately prior to the Spinco Distribution to incorporate such provisions as binding interpretive and/or
administrative provisions so as to enable the parties to give effect to the EMA. 
 4.    This Amendment embodies the
entire agreement between the Parties with respect to the subject matter hereof, provided that the provisions of Article IV of the EMA shall apply hereto as if this Amendment were part of the EMA. 

5.    Except as otherwise expressly provided in this Amendment, the EMA shall continue in full force and effect in
accordance with its terms. 
 6.    This Amendment shall be effective as of immediately prior to the Spinco Distribution
and shall cease to be of any force or effect if and when the Separation Agreement is terminated. 

 B.    NETHERLANDS PENSION MATTERS 

WHEREAS, pursuant to the EMA, Spinco has agreed to Assume effective as of the Closing all rights and obligations under the Middelloonregeling
voor de werknemers van Genencor International B.V. (OFP DuPont European Pension Fund, Netherlands) (the “Genencor NL Plan”); 

WHEREAS, Spinco desires to Assume effective as of the Closing all rights and obligations attributable under the Middelloonregeling voor de
werknemers van DuPont de Nemours (Nederland) B.V., DuPont Filaments Europe B.V., Solae Overseas B.V. (OFP DuPont European Pension Fund, Netherlands) (the “Solae NL Plan”) of those employees of Solae Overseas B.V. who participate in the
Solae NL Plan as of the date hereof and who remain employed as of immediately before Closing by Spinco or an Affiliate thereof, the “In-Scope NL Employees”); and 

WHEREAS, Spinco anticipates that, effective as of the Closing, it will maintain an arrangement (the “Successor Solae Plan”) to
accommodate its Assumption of the Solae NL Plan benefits of the In-Scope NL Employees and that, from and after the Closing, unless and until further modified, the Successor Solae Plan benefits will be
substantially similar to those provided under the Genencor NL Plan from time to time. 
 Accordingly, the Parties agree: 

1.    Spinco will Assume effective as of the Closing all rights and obligations under the Genencor NL Plan notwithstanding
any language in Section 1.06(c)(ii) of the EMA to the contrary. 
 2.    Spinco will Assume effective as of the
Closing all rights and obligations of the In-Scope NL Employees under the Solae NL Plan notwithstanding any language in Section 1.06(c)(ii) of the EMA to the contrary. 

3.    Spinco and Remainco were both entitled to conduct labor negotiations to the extent necessary to permit the Successor
Solae Plan from and after the Closing, unless and until further modified, to provide benefits substantially similar to those provided under the Genencor NL Plan from time to time. 

4.    Effective as of the Closing, Remainco shall cause the trust maintained in respect of the Successor Solae Plan to be
credited with Assets in an amount equal to the total asset value assigned to the DuPont Netherlands section of the DuPont European Pension Fund OFP multiplied by a fraction, the numerator of which is the present value of the accrued benefits under
the Solae Plan of the In-Scope NL Employees as of the Closing and the denominator of which is the present value of all accrued benefits held in the DuPont Netherlands section of the DuPont European Pension
Fund OFP as of the Closing, both calculated in accordance with the applicable financing plan of the DuPont European Pension Fund OFP in effect as of the Closing (the “Solae Pension Assets”). 

  
 2 

 5.    For purposes of determining the Pension Funding Amount, the
Pension Liabilities attributable to the In-Scope NL Employees under the Solae NL Plan (and as applicable the Successor Solae Plan) (the “Solae Pension Liabilities”) shall be deemed to equal the Solae
Pension Assets (such that the Solae NL Plan (and Successor Solae Plan) shall result in neither an increase nor decrease in the Pension Funding Amount). Notwithstanding the foregoing, Remainco shall deliver to Spinco, at or before the time the
Pension Funding Statement is delivered to Spinco, a statement reflecting the Solae Pension Liabilities and Solae Pension Assets (together with information in a manner sufficient to demonstrate how it determined such amounts) in respect of the Solae
NL Plan. Spinco shall have a period of not more than ninety (90) Business Days following delivery of such statement and supporting materials during which to review such statement and supporting materials and to notify Remainco if it believes
the calculation of the Solae Pension Liabilities and/or Solae Pension Assets contains mathematical errors or is based on actuarial or other assumptions inconsistent with the terms of the EMA (as modified by this Amendment) or other otherwise
violates applicable Law. Any such dispute shall be resolved pursuant to the processes and procedures set forth in Section 1.19(b) of the EMA (it being understood and agreed that, for the avoidance of doubt, no such dispute shall have any impact
on the Pension Funding Amount true-up contemplated by Section 1.19(c) of the EMA). 

C.    GERMANY PENSION MATTERS 

WHEREAS, the EMA provides that, in respect of Germany, Remainco shall Assume effective as of Closing the defined benefit pension Liabilities
attributable to Former Spinco Business Employees, exclusive of such Liabilities under the Versorgungsordnung der Pfizer GmbH (the Liabilities to be so Assumed, the “German Former Employee Pension Liabilities”); 

WHEREAS, DDP Specialty Products Germany GmbH & Co. KG and DSP Germany GmbH entered into a demerger agreement (Spaltungs- und
Übernahmvertrag, as notarized November 17, 2020) to effect such Assumption (the “German Pension Demerger Agreement”) in respect of German Former Employee Pension Liabilities determined as of November 30, 2020 (defined in
the German Pension Demerger Agreement as the “Inaktiven Versorgungsberechtigten”); and 
 WHEREAS, the Parties anticipate that,
after November 30, 2020, and before the Closing, one or more employees of DDP Specialty Products Germany GmbH & Co. KG who are Spinco Employees may become Former Spinco Business Employees (the “Interim Retirees”). 

  
 3 

 Accordingly, the Parties agree that: 

1.    For purposes of the EMA, it is intended that the Inaktiven Versorgungsberechtigten are the German Former Employee
Pension Liabilities as of November 30, 2020, and the individuals identified in Annex 1 to the German Pension Demerger Agreement represent the entire and exclusive population in respect of whom such Liabilities are attributable. For the
avoidance of doubt the Parties shall not construe the German Pension Demerger Agreement inconsistently with the foregoing. The Parties agree that if the individuals identified in Annex 1 to the German Pension Demerger Agreement do not in fact
represent the entire and exclusive population in respect of whom the German Former Employee Pension Liabilities as of November 30, 2020 are attributable, then to the extent permitted by the German Pension Demerger Agreement and applicable Law,
the Parties will use reasonable efforts and cooperate with one another in good faith to reform such Annex 1 to have it reflect the entire and exclusive population in respect of whom such German Former Employee Pension Liabilities are attributable.
In any event, to the extent that the Inaktiven Versorgungsberechtigten are not in fact the German Former Employee Pension Liabilities as of November 30, 2020, except as provided in the immediately following paragraph 2, no change to the
provisions of the EMA in respect of the Assumption of German Former Employee Pension Liabilities is intended and the provisions of Section 1.15(b) of the EMA shall apply. Remainco’s obligations under Section 1.15(b) of the EMA shall
not be limited by any obligation of DDP Specialty Products Germany GmbH & Co. KG under the German Pension Demerger Agreement to immediately and completely inform DSP Germany GmbH about any circumstances that could potentially result in
indemnification thereunder or to take all actions of defense against all asserted claims. 
 2.    The German Former
Employee Pension Liabilities in respect of Interim Retirees shall not be Assumed by Remainco and the EMA shall be construed as if Spinco had agreed to Assume such Liabilities as of Closing such that, among other things, such Liabilities (and any
attributable Assets) shall be taken into account for purposes of, and shall be subject to, Section 1.19 of the EMA (Pension Adjustment). 

3.    Except where prohibited by applicable Law, Remainco agrees to provide, as soon as practicable following the date
hereof, Spinco with all information and support reasonably necessary for Spinco to administer the benefits contemplated hereunder to the extent such information is not already under Spinco’s control. 

D.    SOUTH KOREA PENSION MATTERS 

WHEREAS, the EMA provides that, in respect of South Korea, Spinco shall Assume effective as of Closing the defined benefit pension Liabilities
attributable to Spinco Employees; and 
 WHEREAS, the Parties have determined that the portion of the benefit plan (the “Korea DB
Plan”) giving rise to such Liabilities shall not be so Assumed and instead shall be contributed to a defined contribution plan (the “Korea DC Plan”) effective as of the Closing Date on the terms and conditions described herein. 

Accordingly, the Parties agree that: 

1.    Effective as of the Closing, RMT Partner shall cause Spinco to establish or maintain a Korea DC Plan consistent with
the terms of the consents provided by the affected employees. 
 2.    Other than the Assets attributable to the Korea
DB Plan as of the Closing, no other Assets shall be transferred in respect of the Korea DB Plan, in favor of the Korea DC Plan or otherwise. 

  
 4 

 3.    For purposes of Section 1.03(a)(iv) of the EMA, the Korea DC
Plan as in effect upon Closing shall be deemed to have been in effect immediately before Closing but without regard to any one-time special contributions upon establishment of the Korea DC Plan. 

4.    Neither the Korea DB Plan nor the Korea DC Plan (nor any Assets attributable to either) shall be included in the
Pension Funding Statement or the calculation of the Pension Funding Amount. Remainco shall deliver to Spinco, at or before the time the Pension Funding Statement is delivered to Spinco, a statement reflecting the Assets and Liabilities in respect of
the Korea DB Plan that are assumed by, or transferred to, the Korea DC Plan (together with information in a manner sufficient to demonstrate how it determined such amounts). Spinco shall have a period of not more than ninety (90) Business Days
following delivery of such statement and supporting materials during which to review such statement and supporting materials and to notify Remainco if it believes the calculation of such Assets and Liabilities contains mathematical errors or is
based on actuarial or other assumptions inconsistent with the terms of the EMA (as modified by this Amendment) or other otherwise violate applicable Law. Any such dispute shall be resolved pursuant to the processes and procedures set forth in
Section 1.19(b) of the EMA (it being understood and agreed that, for the avoidance of doubt, no such dispute shall have any impact on the Pension Funding Amount true-up contemplated by
Section 1.19(c) of the EMA). 
 E.    JAPAN PENSION MATTERS 

WHEREAS, the EMA provides that, in respect of Japan, Spinco shall Assume effective as of Closing the defined benefit pension Liabilities
attributable to Spinco Employees; and 
 WHEREAS, the Parties have determined that the portion of such funded (but not book reserve cash
balance) defined benefit pension plan (the “Japan DB Plan”) giving rise to such Liabilities shall not be so Assumed and instead shall be contributed to a defined contribution plan (the “Japan DC Plan”) effective as of the Closing
Date on the terms and conditions described herein. 
 Accordingly, the Parties agree that: 

1.    Effective as of the Closing, RMT Partner shall cause Spinco to establish or maintain a Japan DC Plan consistent with
the terms of the consents provided by the affected employees. 
 2.    For purposes of Section 1.03(a)(iv) of the
EMA, the Japan DC Plan as in effect upon Closing shall be deemed to have been in effect immediately before Closing. 

3.    For the avoidance of doubt, the determinations required under Section 1.19(a) of the EMA shall be made after
taking the transactions contemplated by this Item E into account. 

  
 5 

 F.    CERTAIN PENSION PLAN ASSUMPTIONS 

WHEREAS, the Parties wish to clarify the identity of certain defined benefit plans that will be assumed by Spinco in their entirety. 

Accordingly, the Parties agree that, as reflected in Schedule 1.06(c)(i) to the EMA, the following defined benefit plans (including all
Liabilities and any attributable Assets in respect thereof) will be Assumed by Spinco in their entirety effective as of the Closing, notwithstanding any language in Section 1.06(c)(ii) of the EMA to the contrary: (i) Pensionreglement De
Gistfabriek OFP (Genencor Belgium); (ii) Pensionreglement van Danisco Zaandam B.V. (Zwitserleven, Netherlands); and (iii) Danisco (UK) Limited Pension Fund. 

G.    CERTAIN FORMER EMPLOYEE PENSIONS 

WHEREAS, the Parties agreed in Section 1.06(c)(iii)(A) of the EMA that Remainco would Assume all Liabilities and any attributable Assets
in respect of Former Spinco Business Employees under defined benefit pension plans in, among other jurisdictions, Germany; 
 WHEREAS, as
part of its action to effect the Separation, Remainco has caused a member of the Spinco Group to assume sponsorship of the defined benefit pension plans in Germany identified in Parts A and B of Schedule 1.06(c)(i) to the EMA (such plans, the
“German Plans” and the date of such assumption, the “Go-Live Date”) in respect of individuals who were Spinco Employees as of the Go-Live Date (such
Spinco Employees, the “German Participants”); 
 WHEREAS, German Participants who became or become Former Spinco Business
Employees on or following the Go-Live Date and before the Closing Date will continue participation in the German Plans. 

Accordingly, the Parties agree that, except in respect of Interim Retirees described in Item C above, who shall be subject to the provisions
thereof, notwithstanding the provisions of Section 1.06(c)(iii)(A) of the EMA neither the Liabilities under the German Plans in respect of German Participants nor any attributable Assets shall be Assumed by Remainco and the EMA shall be
construed as if Spinco had agreed to Assume such Liabilities as of Closing such that, among other things, such Liabilities (and any attributable Assets) shall be taken into account for purposes of, and shall be subject to, Section 1.19 of the
EMA (Pension Adjustment). 
 H.    WORKERS’ COMPENSATION 

WHEREAS, pursuant to the EMA, Spinco has agreed to Assume effective as of the Closing all Liabilities related to claims for workers’
compensation benefits and coverage which are incurred within the United States prior to the Spinco Distribution Date by Spinco Employees (the “Spinco Employee Pre-Closing WC Claims”); 

WHEREAS, Remainco currently utilizes a professional third party administrator to administer its workers compensation claims including that of
Spinco; 

  
 6 

 WHEREAS, pursuant to the EMA, Spinco has agreed to be responsible for the administration of
all Spinco Employee Pre-Closing WC Claims, or, if Spinco is unable to Assume any such Liability or the administration of any such claim because of applicable Law or Contract, Remainco, or the applicable member
of the Remainco Group, has agreed to administer and/or discharge such Liabilities, as applicable, and Spinco or a member of the Spinco Group has agreed to reimburse Remainco, or the applicable member of the Remainco Group, for all such Liabilities;

 WHEREAS, the Parties have determined that Spinco is legally unable to Assume the Liability for and administration of the Spinco Employee Pre-Closing WC Claims; and 
 WHEREAS, the Parties wish to provide for the terms and conditions on which
Remainco shall cause the administration of, and Spinco will reimburse Remainco for Liabilities incurred in respect of, Spinco Employee Pre-Closing WC Claims. 

Accordingly, the Parties agree that: 

1.    Definitions. For purposes of this paragraph H: 

(a)    “Claim Costs” shall mean all reasonable and documented out-of-pocket costs and expenses (including but not limited to any benefit payments, allocable administrative costs and reasonable and documented attorneys’ fees and costs of the type customarily
incurred by Remainco in the ordinary course of business consistent with its administration of workers compensation claims for Remainco employees) incurred by Remainco or any member of the Remainco Group in connection with the Spinco Employee Pre-Closing WC Claims. 
 (b)    “Remainco” as used in
paragraph 2 below shall refer to Remainco or any member of the Remainco Group that Remainco in its discretion shall identify from time to time to discharge the obligations imposed, or to be the subject of the rights conferred, upon Remainco in such
paragraph 2. 
 2.    Claim Administration; Approvals. 

(a)    Effective from and after the Effective Time, Remainco shall administer and discharge all Spinco
Employee Pre-Closing WC Claims, including without limitation the performance of all governmental reporting and compliance-related activities, in the ordinary course consistent with past practice. 

(b)     As a condition to reimbursement pursuant to paragraph 3 below, for any Claim Costs attributable to
any Spinco Employee Pre-Closing WC Claim to the extent in excess of $100,000 for a calendar quarter, Remainco shall provide notice to RMT Partner and a reasonable opportunity to ask questions, reasonably
request information, and provide comment. 
 (A)    In support of any such notice, Remainco shall
provide Spinco with: (I) the case number and employee name; (II) cost amount; and (III) a summary explanation of the Claim Cost. 

  
 7 

 (B)    If it wishes to do so, Spinco shall respond to
any such notice within five (5) Business Days of receiving the notice and shall be permitted to request that Remainco use commercially reasonable efforts to keep Spinco apprised of the status of such claim and to consult in the ongoing
administration of such claim (such participation not to be unreasonably burdensome, withheld or delayed), in which case Remainco shall, in consultation with Spinco, proceed to administer the claim. 

(C)    If Spinco fails to respond in a timely manner, then Remainco may proceed to administer the claim in
its reasonable discretion. 
 3.    Reimbursement. 

(a)    Spinco shall reimburse Remainco for all Claim Costs in accordance with this paragraph 3. 

(b)    On a quarterly basis (or, at Remainco’s discretion in respect of any Spinco Employee Pre-Closing WC Claim that is settled, at any earlier time following such settlement), Remainco shall present an invoice to Spinco that sets forth all outstanding Claim Costs by reference to case number and employee
name. 
 (c)    Any amount to be reimbursed by Spinco pursuant to this paragraph 3 shall be made
available to Remainco within thirty (30) days after presentation of an invoice in accordance with paragraph 3(b) above. 

4.    Exclusive Treatment. Subject to paragraph 2 of Item A (“GENERAL MATTERS”) above, the
provisions of this Item H shall be the exclusive means by which the Parties discharge obligations under Section 2.05 of the EMA. 

I.    EMPLOYMENT CLAIMS 

WHEREAS, Employee Liabilities, including Liabilities in connection with labor or employment-related Actions, are allocated to Remainco and
Spinco in accordance with Section 1.02 of the EMA; and 
 WHEREAS, depending on the particular Action, it may not be practicable or
possible for the Party who has Assumed Employee Liabilities arising out of such Action or one or more members of its Group (the “Responsible Party”) to remain or become the exclusive named defendant or defendants in such Action. 

  
 8 

 Accordingly, the Parties agree that: 

1.    Except as provided in paragraph 3 below, in respect of labor or employment-related Actions where the Responsible
Party is not the Party (or a member of its Group) that has assumed Liability for the Action under the EMA (“Implicated Actions”), the Parties, or respective members of their Groups in jurisdictions where applicable Implicated Actions are
pending, will jointly determine on a case by case basis whether it is permissible and practicable for the Responsible Party to become the named defendant or defendants in the Implicated Action and, if so, take reasonable steps to substitute the
named defendant or defendants. 
 2.    Except as provided in paragraph 3 below, if applicable Law or the opposing party
does not permit the Responsible Party to become the named defendant or defendants in an Implicated Action or if the Parties are unable to agree whether it is permissible and practicable for the Responsible Party to become the named defendant or
defendants in an Implicated Action or are unable to unilaterally complete the actions to make such change, the provisions of Article VII of the Separation Agreement shall apply in respect of the Implicated Action. 

3.    Employment-related Actions maintained in the United States or Brazil by STD/LTD Employees against a member of the
Spinco Group shall be administered pursuant to the provisions of Article VII of the Separation Agreement on the basis that Remainco is the “Indemnifying Party” and Spinco is the “Indemnitee” within the meaning of Section 7.4
of the Separation Agreement, unless and until the STD/LTD Employee shall have returned to employment in accordance with Section 1.01(d) of the EMA before resolution of the Action, at which time Spinco shall Assume all rights, duties and
Liabilities in respect of such Action as a Spinco Employee Liability in accordance with the proviso at the end of the third sentence of Section 1.01(d) of the EMA. 

J.    VACATION CASHOUT 

WHEREAS, Section 1.07(b) of the EMA provides that, where required by applicable Law or a Spinco Labor Agreement, Remainco or a member of
the Remainco Group shall pay out earned but unused vacation benefits to each Spinco Employee entitled to be paid such benefits by reason of the occurrence of the Spinco Distribution or the Merger (“Required Vacation Payments”) as soon as
practicable following the Spinco Distribution Date, subject to reimbursement by Spinco for the amount of any such Required Vacation Payments; 

WHEREAS, Section 2.01 of the EMA provides that Remainco pay out all U.S. Grandfathered Time to each Spinco Employee in the U.S. as soon
as practicable following the Spinco Distribution; and 
 WHEREAS, as of the Spinco Distribution Date, the Spinco Employees will be employed
by and on the payroll of Spinco or a member of its Group. 
 Accordingly, the Parties agree that 

 

	 	(i)	 Remainco will, as soon as practicable but in no event any later than ten (10) Business Days prior to when
any payment contemplated by clause (ii) hereof, provide to Spinco a statement (the “Vacation Statement”) setting forth all information (including, without limitation, the Spinco Employees to whom such payments are required to be made,
the amount of the required payment and, as applicable, the date by which such payment is required to be made under applicable Law or Spinco Labor Agreement (the “Required Payment Date”)) necessary to properly and timely make any Required
Vacation Payments and U.S. Grandfathered Time, and 

  
 9 

	 	(ii)	 any Required Vacation Payments that have not been paid prior to the Spinco Distribution Date and any U.S.
Grandfathered Time shall be paid to the applicable Spinco Employees by Spinco by the Required Payment Date or, if there is no Required Payment Date, as soon as practicable following the Spinco Distribution in full satisfaction of the Parties’
obligations under Sections 1.07(b) and 2.01 of the EMA; provided, however, that the foregoing notwithstanding, Remainco shall indemnify Spinco for any Liability incurred by Spinco as a result of 

 

	 	(x)	 the failure to make any payment due under Section 1.07(b) or 2.01 of the EMA by the date required under
applicable Law or Spinco Labor Agreement to the extent such failure occurred prior to the Closing Date, or 

  

	 	(y)	 any error in the Vacation Statement. 

K.    CORPORATE/FUNCTIONAL EMPLOYEES 

WHEREAS, Section 1.01(a)(ii) of the EMA provides that individuals identified, through a process mutually agreed by the Parties for talent
selection, to fill shared corporate or functional department roles set forth on Schedule 1.01(a)(ii) shall be Spinco Employees; and 

WHEREAS, Remainco and RMT Partner have had meetings and communications regarding the talent selection process and have considered the number
and type of corporate and functional roles. 
 Accordingly, the Parties agree that (i) approximately 1,059 employees in shared
corporate and functional department roles (less any voluntary departures or other terminations of such employees, to the extent not restricted by Section 8.2(b)(xii) of the Merger Agreement, between January 11, 2021 and the Closing Date)
are designated as Spinco Employees (not the estimated 1,458 employees in shared corporate and functional department roles set forth on Schedule 1.01(a)(ii) to the EMA), and (ii) such final number of employees in shared corporate and functional
department roles designated as Spinco Employees shall be reflected on the final census of Spinco Employees made available by Remainco in accordance with Section 1.01(a) of the EMA. 

L.    CERTAIN REIMBURSEMENTS 

WHEREAS, Section 1.15(b) of the EMA acknowledges that in certain circumstances a Party may incur a Liability that it has not Assumed
pursuant to the EMA and that, in such circumstances, the Parties shall promptly reimburse one another as further described in such Section 1.15(b); and 

  
 10 

 WHEREAS, the Parties wish to agree upon how payment in respect of certain such Liabilities
shall be made and how such reimbursement shall be effected, as further described below in this Item K. 
 Accordingly, the Parties agree
that: 
 1.    Spinco shall pay (or cause one of its Affiliates to pay) any amounts described in the first sentence of
Section 1.06(e) of the EMA that first become payable on or after the Closing Date, and Remainco shall reimburse Spinco therefor in accordance with Section 1.15(b) of the EMA. 

2.    Remainco shall make (or cause one of its Affiliates to make) payment in respect of claims under Remainco’s U.S.
welfare benefit plans described in Section 1.11(a) of the EMA, and Spinco shall reimburse Remainco therefor in accordance with Section 1.15(b) of the EMA. 

M.    NON-CONSENTING EMPLOYEE SEVERANCE 

WHEREAS, Section 1.08(b) of the EMA obligates Remainco to Assume certain severance obligations subject to reimbursement by Spinco in
certain circumstances; and 
 WHEREAS, the Parties desire to agree on a limited amendment to Section 1.08(b). 

Accordingly, the Parties agree that the reference in Section 1.08(b)(ii) of the EMA to “three (3) months” shall be deemed
a reference to “eight (8) months” in respect of any Non-Consenting Employee where the amount of severance payable to the Non-Consenting Employee is less
if the Non-Consenting Employee’s employment is terminated between three (3) months to eight (8) months following the Closing Date. 

N.    CERTAIN OTHER SEVERANCE 

WHEREAS, Spinco is obligated under the EMA to Assume, and as applicable reimburse Remainco in full for, severance payable to Former Spinco
Employees after the Closing in respect of a termination of employment before the Closing to the extent such severance is not described in Section 1.08(b) of the EMA; and 

WHEREAS, Remainco may determine in certain circumstances, for administrative convenience of Spinco or otherwise, to pay before the Closing
severance amounts described in the preceding recital. 
 Accordingly, the Parties wish to expressly acknowledge that, to the extent Remainco
pays such severance before the Closing, it shall remain subject to reimbursement by Spinco after the Closing; provided that in each such case, the amount of severance Remainco pays prior to the Closing does not exceed the amount that would have been
required to have been paid had such severance been paid following the Closing, as contemplated by the EMA. 

  
 11 

 O.    U.S. CARES ACT PAYROLL TAX DEFERRALS 

WHEREAS, certain members of the Remainco Group and Spinco Group, respectively, have delayed the payment of employer payroll taxes as permitted
under Section 2302 of the U.S. CARES Act; and 
 WHEREAS, the obligation to make deferred payment of such taxes in respect of Spinco
Employees or Former Spinco Business Employees is a Spinco Employee Liability (the “Spinco Deferred Payroll Liability”) and the obligation of any member of the Remainco Group or Spinco Group to make deferred payment of such tax in respect
of any other individual is a Remainco Employee Liability the (“Remainco Deferred Payroll Liability”). 
 Accordingly, the Parties
agree that: 
 1.    Not more than forty-five (45) days after Remainco provides to RMT Partner proof of payment to
the Internal Revenue Service of a Spinco Deferred Payroll Liability along with supporting documentation that reasonably demonstrates the amount of the Spinco Deferred Payroll Liability, RMT Partner shall cause Spinco to reimburse Remainco such
amount. 
 2.    Not more than forty-five (45) days after Spinco provides to Remainco proof of payment to the
Internal Revenue Service of a Remainco Deferred Payroll Liability along with supporting documentation that reasonably demonstrates the amount of the Remainco Deferred Payroll Liability, Remainco shall reimburse Spinco such amount. 

3.    Any demonstration of payment of a Remainco Deferred Payroll Liability or Spinco Deferred Payroll Liability, as the
case may be, must be made not later than March 31, 2022 in the case of amounts owing the Internal Revenue Service on or before December 31, 2021, and not later than March 31, 2023 in the case of amounts owing the Internal Revenue
Service on or before December 31, 2022. 
 4.    From and after the Closing, no Party shall assert that any
obligation to make deferred payment of employer payroll taxes as permitted under Section 2302 of the U.S. CARES Act is subject to reimbursement among the Parties other than to the extent provided in the foregoing provisions of this Item O. 

P.    CERTAIN STOCK OPTION HOLDERS 

WHEREAS, Section 1.10(f)(ii) of the EMA provides that Spinco shall take commercially reasonable efforts to inform Remainco of a
termination of employment that occurs before March 1, 2021, of certain Spinco Employees who hold Conversion Equity Awards (the “Schedule 1.10(f)(ii) Employees”); and 

WHEREAS, the Parties wish to provide that such employment termination information will be provided in respect of any employment termination
that occurs after February 28, 2021 and on or before January 1, 2029, in respect of those Schedule 1.10(f)(ii) Employees identified on Schedule A hereto by current employee identification number. 

  
 12 

 Accordingly, the Parties agree that Spinco shall take commercially reasonable efforts to
inform Remainco of a termination of employment that occurs after February 28, 2021, and before January 1, 2029, of any Schedule 1.10(f)(ii) Employee identified on Schedule A hereto. 

Q.    WARN LIST 

WHEREAS, Section 2.06 of the EMA requires Remainco to provide the WARN List, including the name and site of employment of certain U.S.
employees who have experienced an employment loss or layoff as defined by the WARN Act within ninety (90) days prior to the Closing Date; 

WHEREAS, to preserve individual privacy, and because it is not necessary for RMT Partner or Spinco to receive the names (as opposed to
employee identification numbers) of individuals who have experienced an employment loss or layoff under WARN, Remainco believes it would be prudent to provide employee identification numbers in lieu of individual names on the WARN List; and 

WHEREAS, for administrative convenience Remainco has requested an additional five (5) Business Days within which to deliver the WARN
List. 
 Accordingly, the Parties agree that Remainco shall provide employee identification numbers in lieu of employee names on the WARN
List and that, notwithstanding anything in Section 2.06 of the EMA to contrary, Remainco shall deliver such WARN List to Spinco no later than five (5) Business Days following the Closing Date. For the avoidance of doubt, the Parties agree
that the WARN List will also contain applicable sites of employment in accordance with Section 2.06 of the EMA. 
 R.    Non-Consenting Employee Severance List 
 WHEREAS, Section 1.13(b) of the EMA provides for certain
restrictions on RMT Partner and Spinco in respect of the solicitation and hiring of Non-Consenting Employees; and 

WHEREAS, in order for RMT Partner and Spinco to comply with their obligation not to hire, within the first twelve (12) months of the Non-Solicitation Period, any Non-Consenting Employee described in Section 1.13(b)(i)(B) of the EMA, the Parties agree that Remainco shall provide to Spinco and RMT
Partner a running list of such Non-Consenting Employees. 
 Accordingly, the Parties agree that the
final census made available by Remainco in accordance with Section 1.01(a) of the EMA shall include a written list of the names of each Non-Consenting Employee described in Section 1.13(b)(1)(B) of
the EMA and Remainco shall promptly provide Spinco and RMT Partner with an updated list as and to the extent any additional Non-Consenting Employee described in Section 1.13(b)(1)(B) of the EMA is
identified. 

  
 13 

 S.    LTI Information for Census 

WHEREAS, pursuant to Section 1.01(a) of the EMA, Remainco is required to provide Spinco and RMT Partner with a final census that includes,
among other things, the target long-term incentive opportunity for 2020 with respect to each Spinco Employee (the “LTI Information”); and 

WHEREAS, Remainco previously provided such LTI Information in the HR Master data files previously provided to RMT Partner and has requested
that Remainco not be required to duplicate such LTI Information on the final census to be provided by Remainco in accordance with Section 1.01(a) of the EMA. 

Accordingly, the Parties hereby agree that Remainco is permitted to provide the LTI Information in a written format separate and apart from
the census contemplated by Section 1.01(a) of the EMA, and the LTI Information included in the HR Master data files previously provided to RMT Partner satisfies such obligation; it being understood and agreed that Remainco shall continue to
have such rights, obligations and Liabilities in respect of the accuracy of the LTI Information included in such HR Master data files as if such information had been provided pursuant to the census contemplated by Section 1.01(a) of the EMA as
originally contemplated therein. 
 T.    Rabbi Trust 

WHEREAS, Section 2.04 of the EMA requires Spinco or RMT Partner to establish the New Rabbi Trust and requires Remainco to direct the
trustee of the Existing Rabbi Trust to Transfer certain Assets in-kind to the trustee of the New Rabbi Trust; and 

WHEREAS, the Parties have determined that such Transfer should be made in cash or cash equivalents rather than
in-kind. 
 Accordingly, the Parties hereby agree that such Transfer of Assets shall be made in cash
or cash equivalents rather than in-kind and otherwise in accordance with Section 2.04 of the EMA. 

* * * 

  
 14 

 IN WITNESS WHEREOF, the Parties have caused this Amendment to be duly executed as of the day
and year first above written. 
  

			
	DUPONT DE NEMOURS, INC.
		
	By:	 	 /s/ Lori Koch

	Name:	 	Lori D. Koch
	Title:	 	Executive Vice President and Chief Financial Officer

  
 [Signature Page to
Amendment to the Employee Matters Agreement] 

 
			
	
	NUTRITION & BIOSCIENCES, INC.
		
	By:	 	 /s/ Lori Koch

	Name:	 	Lori D. Koch
	Title:	 	Executive Vice President and Chief Financial Officer

  
 [Signature Page to
Amendment to the Employee Matters Agreement] 

 
			
	
	INTERNATIONAL FLAVORS & FRAGRANCES INC.
		
	By:	 	 /s/ Rustom Jilla

	Name:	 	Rustom Jilla
	Title:	 	Chief Financial Officer

  
 [Signature Page to
Amendment to the Employee Matters Agreement]Exhibit 10.1

 

**CERTAIN INFORMATION, MARKED BY [***],
HAS BEEN EXCLUDED BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.**

 

EVALUATION
Agreement

 

This Evaluation Agreement (“Agreement”)
is between Illumina, Inc., having offices at [***] (“Illumina") and Aptorum Innovations Holding Limited, having offices
at 4T.07, 17 Hanover Square, Mayfair, London, United Kingdom W1S 1BN (“AIHL”), and is effective as of the date of last
signature below ("Effective Date"). Illumina and AIHL may be referred to individually as a “Party” or collectively
as “Parties.”

 

		1.	Details

 

	Evaluation Product:	 	
        [***]

        (collectively referred to herein
as the “Evaluation Product”)

	 	 	 
	Purpose of Evaluation:	 	
        Illumina wishes to send to the
        Facility, and the Facility wishes to receive, the Evaluation Product to enable AIHL and the Facility (“Evaluation
        Site”) to evaluate and/or familiarise themselves with the appropriate use and functionality of the Evaluation Product
        (“Evaluation”). Evaluation Site will provide to Illumina Feedback relating to Evaluation Site’s experience
        with the Evaluation Product. “Feedback” is defined in section 6.5 below.

	 	 	 
	Fees for Evaluation:	 	Illumina will provide the Evaluation Product free of charge.
	 	 	 
	Evaluation Period:	 	Evaluation Site shall undertake the Evaluation of the Evaluation Product for a period of [***] from the date of recipient of the Evaluation Product and all Equipment (if any) required to perform the Evaluation. 
	 	 	 
	AIHL Contact Information:	 	
        Name: Darren Lui, Director

        Tel: 

        Email:

	 	 	 
	Evaluation Site Facility where Evaluation Product shall be located:	 	 [***] (“Facility”)

 

		2.	Evaluation Plan

 

		2.1	The Evaluation shall be conducted in accordance with
this Agreement and the “Evaluation Plan” attached at Exhibit A.

 

		3.	Delivery and
Installation

 

		3.1	Evaluation Product. Illumina will prepare and
deliver the Evaluation Product to the Facility identified above (“Delivery”). For Evaluation Products which require
installation by Illumina, Illumina will support such installation at that Facility on a mutually convenient date. Any Delivery
or installation date or time provided by Illumina is an estimate only and time will not be of the essence for Delivery or installation.
Evaluation Site will provide to Illumina all of the necessary technical information, network and computer facilities and access
to premises and personnel as Illumina may reasonably require to effect Delivery and installation.

 

		3.2	Equipment. In the event Illumina loans Evaluation
Site hardware or other laboratory equipment (“Equipment”) in order to enable Evaluation Site to undertake the Evaluation,
then such Equipment shall be stated in the Evaluation Plan. Risk in the Equipment passes to the Evaluation Site on Delivery, and
Evaluation Site shall be liable to Illumina for all loss or damage to the Equipment during the Term and until return to Illumina,
or a third party if so directed by Illumina, less reasonable wear and tear. Accordingly, Evaluation Site shall ensure it has an
appropriate insurance policy in place at least equal to the value of the loaned Equipment to cover any such loss or damage it
is liable for under this Agreement. Illumina may request return of the Equipment at any time. Illumina shall loan any Equipment
specified in the Evaluation Plan for free of charge.

 

     

     

    

 

**CERTAIN INFORMATION, MARKED BY [***],
HAS BEEN EXCLUDED BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.**

 

		4.	Use of Evaluation Product

 

		4.1	Evaluation. Subject to this Agreement, Evaluation Site shall be permitted to use the Evaluation
Product, together with any user manual, package insert, and similar technical documentation (“Documentation”) solely
for the Evaluation and for no other purposes. Documentation may be provided with the Evaluation Product at time of Delivery, or
installation, or provided electronically from Illumina. Evaluation Site shall not move the Evaluation Product from the Facility
without the prior written approval of Illumina.

 

		4.2	Research Use Only. The Evaluation Product is labelled with a “For Research Use Only”
or similar labelling statement and has not been approved, cleared, or licensed by any regulatory authority. The Evaluation Product
is not appropriate for clinical or diagnostic use of human subjects. Evaluation Site will not use the Evaluation Product in any
manner inconsistent with its labelling as a product only for research use. Evaluation Site agrees to comply with all applicable
local laws and regulations when using the Evaluation Product. Evaluation Site will not bill for or seek reimbursement for the Evaluation
Product from any insurer, whether government or private, third party payor, or any other entity.

 

		4.3	Restrictions on Use. Evaluation Site agrees not to engage in any of the following activities:
(a) disassemble, reverse-engineer, reverse-compile, or reverse-assemble the Evaluation Product, (b) separate, extract, or isolate
components of the Evaluation Product or subject the Evaluation Product or components thereof to any analysis not expressly authorized
in any Documentation, (c) gain access to or attempt to determine the methods of operation of the Evaluation Product, (d) transfer
to a third-party, sell, or grant a sublicense to, the Evaluation Product (including any component thereof, including any software
or third party software), or (e) use the Evaluation Product for any use not specified or authorized in the Documentation, or otherwise
in any manner which is inconsistent with the Documentation.

 

		4.4	No License. Nothing in this Agreement grants Evaluation Site a license to any intellectual
property owned or controlled by Illumina or Illumina's Affiliates or a third party whether by implication, estoppel, or otherwise
with respect to such use of the Evaluation Product. “Affiliate” shall mean any company controlling, controlled by or
under common control with the relevant Party where control means the power to direct or cause the direction of the management and
policies of such entity whether by contract or otherwise. The Parties each agree to be responsible for actions and omissions of
its Affiliates.

 

		4.5	Equipment. Any Equipment loaned in connection with the Evaluation shall also be subject
to the same provisions as this section 4.

 

		5.	CONFIDENTIALITY

 

		5.1	Confidential Information. As used in this Agreement, “Confidential Information”
means all information and Evaluation Product (whether technical or non-technical) disclosed by the disclosing Party (“Disclosing
Party”) to the receiving Party (“Receiving Party”) in connection with this Agreement that is confidential in
nature. Such Confidential Information includes, without limitation, trade secrets, processes and methodologies, formulas, data,
know-how, software, documentation, program files, flow/charts, drawings, software techniques and other techniques, computer programs,
standards, specifications, improvements, inventions, accounting data, statistical data, research projects, development and marketing
plans, strategies, forecasts, sales, costs, profits, and pricing methods and organizations, employee lists, or compensation plans,
and shall be clearly and prominently marked with the word "Confidential" or with such other words of similar import.
Any Confidential Information not being capable of being so marked, including Confidential Information which may be orally or visually
disclosed, shall, within fourteen (14) days of its disclosure be summarised in writing, be marked with the word "Confidential"
or with such other words of similar import and delivered by the Disclosing Party to the Receiving Party, provided that any such
Confidential Information shall be treated as being confidential immediately upon disclosure.

 

		5.2	Non-Disclosure Obligations. For a period of [***] from the date of disclosure, each Party
agrees to hold the other’s Confidential Information in confidence, to use it only in connection with the Evaluation, and
to use at least the same degree of care and protection as it uses to prevent unauthorized use and unauthorized disclosure of its
own confidential information of like importance, but in no case less than a reasonable degree of care. Neither Party shall disclose
the other Party’s Confidential Information to any third party without the express prior written consent of the disclosing
Party. Where Evaluation Site is the receiving Party, Evaluation Site may disclose Confidential Information but only for auditing
and reporting purposes and after notifying and obtaining Illumina’s consent. Neither Party shall copy, decompile, disassemble
or reverse engineer any Confidential Information of the other Party without the express prior written consent of the disclosing
Party.

 

    2

     

    

 

**CERTAIN INFORMATION, MARKED BY [***],
HAS BEEN EXCLUDED BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.**

 

		5.3	Exclusions. Categories of information specifically excluded from the obligations of confidentiality
under this Agreement are information that a receiving Party can demonstrate by competent written evidence (a) was in the possession
of the receiving Party prior to disclosure by the disclosing Party, (b) is or subsequently becomes part of the public domain through
no action or inaction of the receiving Party, (c) becomes known to the receiving Party through a third party who is not under any
obligation of confidentiality to the disclosing Party, or (d) is developed by or for the receiving Party without reference to the
disclosing Party’s Confidential Information.

 

		5.4	Disclosure Required by Law. A receiving Party may disclose the other Party’s Confidential
Information if is required to be disclosed by a valid order of a court or other governmental body having jurisdiction or a regulatory
authority, provided such receiving Party uses best efforts to limit such disclosure and, as soon as reasonably possible, notifies
the other Party of such requirement to allow the disclosing Party the opportunity to assert the confidential nature of the information
and to seek an appropriate protective order. AIHL or its holding company (Aptorum Group Limited) may disclose the terms and conditions
of this Agreement, with prior written notification to the other Party should this type of disclosure be necessary, (i) in any governmental
filing or to other authorities as required by the applicable laws and/or regulation or rules of NASDAQ, Euronext Paris, the Financial
Industry Regulatory Authority, the U.S. Securities and Exchange Commission and/or the French Autorité des marchés
financiers, or (ii) in connection with any action or claim to enforce its rights thereunder. For the avoidance of doubt, the content
of any disclosure will not contain data on the Feedback unless prior consent is obtained from Illumina.

 

		6.	Ownership

 

		6.1	Evaluation Product. Illumina owns and retains all right, title, and interest in and to the
Evaluation Product. The transfer of the Evaluation Product by Illumina to Evaluation Site will not constitute a sale or offer for
sale of the Evaluation Product, in whole or in part, or an option or license in or to any such Evaluation Product or any information
or intellectual property relating thereto. Further, Illumina makes no guarantee that any Evaluation Product will be made commercially
available at a later date.

 

		6.2	Background IP. Each Party owns and retains all right, title, and interest in and to such
Party’s Background IP and Confidential Information. Except as expressly set forth in this Agreement no Party grants to another
Party any right, title, license or interest in or to its Background IP or Confidential Information. “Background IP”
means any and all intellectual property of any nature owned or controlled by a Party or its Affiliates prior to the Effective Date,
or intellectual property that arises outside of this Agreement and is owned or controlled by such Party or its Affiliates after
the Effective Date. For clarity, no Background IP of the Evaluation Site is required or expected for conducting the Evaluation.

 

		6.3	License. Subject to the limitation hereunder, Illumina grants to the Evaluation Site a limited,
non-exclusive, royalty-free license under its Background IP to use the Evaluation Product during the Evaluation Period solely to
conduct the Evaluation Plan.

 

		6.4	Equipment. The Equipment will throughout the Evaluation Period and following termination
or expiry of this Agreement remain the property of Illumina. Evaluation will use no less than a reasonable degree of care to protect
and maintain any loaned Equipment, and: (a) will not damage or destroy the Equipment, nor permit it to be damaged or destroyed,
(b) will not create or permit to be created or arise any lien, mortgage, pledge, security interest, assignment, restriction, charge,
or other encumbrance or right exercisable by a third party having similar effect, over or relating to the Equipment, (c) will not
permit the Equipment to fix, bind or enure to any realty or land, and (d) will not sell or alienate the Equipment. Evaluation Site
will be responsible for any loss, damage, cost and expense (including reasonable legal fees) suffered or incurred by Illumina as
a result of or in connection with the Evaluation Site’s breach of this section 6.3.

 

		6.5	Proprietary Information. The contents, design, materials, properties, formulation, methods
and techniques of operation and manufacture of the Evaluation Product are the proprietary and trade secret information of Illumina
and may not be disclosed by Evaluation Site to any third party or be used in any manner not authorized in writing by Illumina (“Proprietary
Information”). Proprietary Information is the Confidential Information of Illumina. Notwithstanding anything to the contrary,
Evaluation Site will not disclose Proprietary Information to any third party, or use the Proprietary Information in any manner
other than in its performance under this Agreement, at any time. To the extent that any Feedback is publishable data, written consent
from the other Party is required prior to such publication by the publishing Party.

 

		6.6	Improvements. Illumina will own all right, title, and interest in and to any and all improvements,
modifications, or enhancements to the Evaluation Product and any and all intellectual property included in, embodied by, or related
thereto. Evaluation Site hereby assigns and agrees to assign to Illumina (from the moment of creation) all right, title, and interest
in and to such improvements, modifications, and enhancements, and intellectual property included therein, embodied, or related
thereto, and agrees to execute any documentation reasonably requested by Illumina to further document such assignment.

 

    3

     

    

 

**CERTAIN INFORMATION, MARKED BY [***],
HAS BEEN EXCLUDED BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.**

 

		6.7	Feedback. Evaluation Site shall provide Illumina a report describing Evaluation Site’s
use of and the performance of the Evaluation Product, as detailed in the Evaluation Plan (“Feedback”). Evaluation Site
shall not include any personal data of any natural person in the Feedback. Illumina may use the Feedback for any use, including
commercial purposes, and to make improvements, modifications, enhancements, and derivatives of or to the Evaluation Product. All
Feedback shall be owned by, and be the Confidential Information of, Illumina.

 

		7.	Publicity; Publication

 

		7.1	Evaluation Site may not disclose the existence or the contents of this Agreement to any third party
without Illumina’s prior written consent. Notwithstanding anything to the contrary, Evaluation Site may disclose to its Affiliates
the existence and contents of this Agreement, but not the Confidential Information except in accordance with section 5. This requirement
for consent shall not apply to the extent that such disclosure is required to comply with applicable law, or because such information
is requested by a court order, a regulator, or a government body, as detailed in section 5.4 of this Agreement.

 

		7.2	Subject to section 6.7 above, Evaluation Site may not publish any publication regarding the Evaluation,
or Evaluation Product, or Feedback without Illumina’s prior written consent.

 

		7.3	Evaluation Site agrees that Illumina may use its name as well as the name, contact information,
professional qualifications, and occupation of any employees of Evaluation Site (collectively, “Evaluation Site Information”)
involved in the Evaluation for advertising of the Evaluation Product, marketing of Illumina products and services (to the extent
that the Evaluation relates to Illumina products and services), publications, internal Illumina websites, third party websites,
leaflets, flyers, and any other marketing materials in any format or by any technology that now exists or in the future may exist,
training, improvements to products and services, and future Illumina sponsored events. Notwithstanding the foregoing, any use of
the Evaluation Site Information shall be subject to prior review and written approval, not unreasonably withheld, by the Evaluation
Site, and Illumina will cease to use any Evaluation Site Information immediately upon notice.

 

		8.	Term; Termination

 

		8.1	The term of this Agreement will begin on the Effective Date and continue throughout the Evaluation
Period, unless earlier terminated by either Party upon [***] written notice to the other Party. The Parties may extend the Evaluation
Period in writing and upon mutual agreement. Expiration or termination of this Agreement will not relieve the Parties of any obligation
accruing prior to such expiration or termination. In addition, sections 4 through 10 of this Agreement will survive the termination
or expiration of this Agreement. Upon termination or expiration of this Agreement, or earlier upon Illumina’s request, Evaluation
Site will return to Illumina all Equipment, Evaluation Product, Proprietary Information, and Illumina Confidential Information
in its possession. Upon termination or expiration of this Agreement, or earlier upon Evaluation Site’s request, Illumina
will return or destroy Evaluation Site’s Confidential Information in its possession. When returning any borrowed Equipment
to Illumina, Evaluation Site shall exercise all reasonable care and skill and will comply with Illumina’s instructions for
decommissioning, packing and shipping the Equipment. Risk in the returned Equipment passes from Evaluation Site to Illumina upon
delivery at Illumina’s nominated return address.

 

		8.2	Whilst Illumina will provide reasonable assistance during deinstallation to explain how to perform
deletion of Evaluation Site’s data from the Equipment and/or Evaluation Product (if any), ILLUMINA SHALL NOT BE RESPONSIBLE
FOR MAINTAINING OR PROTECTING ANY CONFIGURATION SETTINGS OR DATA FOUND ON THE RETURNED EQUIPMENT, EVALUATION PRODUCT OR COMPONENT
PART OF THE EQUIPMENT OR EVALUATION PRODUCT AND IT IS EVALUATION SITE’S SOLE RESPONSIBILITY TO DELETE ANY SUCH INFORMATION
PRIOR TO RETURN.

 

		8.3	If Evaluation Site fails to comply with the provisions of section 8.1, Illumina will have a right
of peaceable entry to the Facility during normal business hours to deinstall (where applicable) and pack up the Equipment and Evaluation
Product and return it to Illumina, at Evaluation Site’s cost. Notwithstanding the foregoing, if Illumina is refused entry
by Evaluation Site then Illumina shall be entitled to invoice the Evaluation Site, and Evaluation Site shall be required to pay,
for the list price of the Equipment that has not been returned to Illumina by the agreed upon date of return.

 

    4

     

    

 

**CERTAIN INFORMATION, MARKED BY [***],
HAS BEEN EXCLUDED BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.**

 

		9.	Liability

 

		9.1	EVALUATION Site acknowledges that it is the nature of this
Evaluation that the EVALUATION Product and any Equipment is provided strictly “as-is”, and, to the fullest extent permitted
by applicable law, Illumina makes no (and expressly disclaims all) warranties, express, implied or statutory, with respect to the
EVALUATION Product and any Equipment, including without limitation, any warranty of merchantability, fitness for a particular purpose,
noninfringement, or warranties arising from course of performance, dealing, usage or trade, its functionality, or its suitability
to the EVALUATION SITE’S requirements. Illumina makes no claim, representation or warranty of any kind as to the utility
of the EVALUATION product or any Equipment for EVALUATION Site’s intended use. 

 

		9.2	Nothing in this Agreement will limit or exclude either Party’s liability for a violation
of the other Party’s intellectual property rights, for fraud, or any liability which cannot be limited or excluded by law.
, NEITHER PARTY will have liability for any loss of profits or revenue, any account of
profits, any increased costs, any loss of anticipated savings, any loss of opportunity, any loss of goodwill or reputation, any
loss or corruption of data, nor for any indirect or consequential loss, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (WHETHER
IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE), and EACH PARTY’s maximum aggregate liability to
the OTHER PARTY arising out of or in connection with this Agreement will be limited to £5,000 (Five-Thousand Great British
Pounds) or its equivalent in other currencies as of the effective date. 

 

		10.	GENERAL

 

		10.1	Notice. Any notice given under this Agreement must be in writing and delivered to the attention
of the legal department of the Party to whom notice is to be given at the address set forth above (or at such other address such
Party may provide from time to time) via email, certified mail return receipt requested, or via overnight courier in accordance
with this section 10.1. Any notice will be deemed to have been given as of the date delivered by hand, or on the second business
day (at the place of delivery) after deposit with an internationally recognized overnight delivery service, whichever is earlier.

 

		10.2	Governing Law. This Agreement is governed by, construed, and enforced in accordance with
the laws of the State of California of the United States. The Parties irrevocably consent to the non-exclusive jurisdiction of
the state and federal courts located in San Diego, California, USA for the purpose of any action brought in connection with this
Agreement.

 

		10.3	Assignment. This Agreement may not be assigned by either Party in whole or in part without
the prior written consent of the other Party, except that Illumina may assign this Agreement and its rights and obligations hereunder
to any of its Affiliates or any successor in interest (whether by merger, acquisition, asset purchase or otherwise) to all or substantially
all of the business to which this Agreement relates. Any purported assignment of this Agreement in violation of this section 10.3
will be void and of no effect. Illumina may perform any or all of its obligations and exercise any or all of its rights under this
Agreement through any of its Affiliates.

 

		10.4	Equitable Relief. A breach by either Party of sections 4, 5 and 6 of this Agreement may
cause irreparable damage and the non-breaching Party may not be adequately compensated by monetary damages. In the event of a breach,
or threatened breach, of sections 4, 5 and 6, the non-breaching Party will be entitled to seek equitable relief, without the requirement
of having to post a bond or other security. Nothing in this section 10.4 is intended, or will be construed, to limit the Parties’
rights to equitable relief or any other remedy for a breach of any provision of this Agreement.

 

		10.5	Miscellaneous. This Agreement represents the entire understanding between the Parties with
respect to the subject matter hereof. The Parties are independent contractors and are engaged in the operation of their own respective
businesses, and neither Party is to be considered the agent of the other Party. Neither Party has any authority to enter into any
contract or assume any obligation for or on behalf of the other Party. This Agreement may not be amended except by a writing signed
by authorized representatives of both Parties. A Party will not be deemed to have waived any right under this Agreement unless
the waiver is in a writing signed by an authorized representative of such Party. If any provision of this Agreement is held illegal,
invalid or unenforceable by a court of competent jurisdiction, or in conflict with any law of a federal, state, or local government
with competent jurisdiction, such provision will be stricken and replaced with a provision designed to carry out the initial intent
of the Parties. The validity of the remaining portions or provisions hereof will not be affected thereby. As used in this Agreement,
unless otherwise indicated, “including” means including without limitation; and “will” and “shall”
are used synonymously. If any date of performance or delivery under this Agreement falls on a weekend or holiday recognized in
the country where the Illumina entity which is a Party to this Agreement is incorporated, then the date of performance or delivery
will be due on the first business day following such weekend or holiday. This Agreement may be executed in one or more counterparts,
each of which when executed and delivered by electronic transmission or mail delivery, will be an original and all of which will
constitute one and the same instrument. The Parties agree that execution of this Agreement by industry standard electronic signature
software shall have the same legal force and effect as the exchange of original signatures, and that in any proceeding arising
under or related to this Agreement, each Party hereby waives any right to raise any defence or waiver based upon execution of this
Agreement by means of such electronic signatures or maintenance of the executed agreement electronically.

 

    5

     

    

 

**CERTAIN INFORMATION, MARKED BY [***],
HAS BEEN EXCLUDED BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.**

 

	Aptorum innovations holding limited	 	ILLUMINA, INC.

 

	By:	 	 	By:	 
	 	 	 	 	 
	Name: 	 	 	Name: 	 
	 	 	 	 	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	Date:	 	 	Date:	 

 

	Contact for EVALUATION SITE:	 	CONTACT FOR ILLUMINA:

 

	Name:
	 	Name: 
	 	 	 
	Title: 	 	Title: 
	 	 	 
	Phone: 	 	Phone: 
	 	 	 
	Email: 	 	Email: 

 

Exhibit A

 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]